Vertex and treefrog therapeutics announce licensing agreement and collaboration to optimize production of vertex's cell therapies for type 1 diabetes

Vertex obtains an exclusive license to treefrog's c-stemtm  manufacturing technology in type 1 diabetes  treefrog and vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells  boston and bordeaux, france , april 23, 2024 /prnewswire/ -- vertex pharmaceuticals incorporated (nasdaq: vrtx) and treefrog therapeutics today announced that vertex has obtained an exclusive license to treefrog's proprietary cell manufacturing technology, c-stemtm, to optimize production of vertex's cell therapies for type 1 diabetes (t1d). treefrog and vertex will collaborate to scale-up treefrog's process to produce and amplify cells for vertex's t1d therapies.
VRTX Ratings Summary
VRTX Quant Ranking